What is Arrivent Biopharma Inc's earnings per share (EPS)?

Arrivent Biopharma Inc (AVBP) reported diluted earnings per share of $-4.32 for fiscal year 2025. This represents a -68.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Arrivent Biopharma Inc Financials

AVBP

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Arrivent Biopharma Inc (AVBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Arrivent Biopharma Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.97x

For every $1 of reported earnings, Arrivent Biopharma Inc generates $0.97 in operating cash flow (-$160.6M OCF vs -$166.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$180.6M

Arrivent Biopharma Inc's EBITDA was -$180.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

-$166.3M

YoY-106.6%

Arrivent Biopharma Inc reported -$166.3M in net income in fiscal year 2025. This represents a decrease of 106.6% from the prior year.

EPS (Diluted)

$-4.32

YoY-68.8%

Arrivent Biopharma Inc earned $-4.32 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 68.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$45.5M

YoY-38.7%

Arrivent Biopharma Inc held $45.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

42M

YoY+25.9%

Arrivent Biopharma Inc had 42M shares outstanding in fiscal year 2025. This represents an increase of 25.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-54.1%

YoY-22.9pp

Arrivent Biopharma Inc's ROE was -54.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 22.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$153.4M

YoY+94.1%

Arrivent Biopharma Inc invested $153.4M in research and development in fiscal year 2025. This represents an increase of 94.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

AVBP Income Statement

Metric	FY25	FY24	FY23
Revenue	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	$153.4M+94.1%	$79.0M+21.8%	$64.9M
SG&A Expenses	$24.2M+58.0%	$15.3M+57.7%	$9.7M
Operating Income	-$177.5M-88.2%	-$94.3M-26.4%	-$74.6M
Interest Expense	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A
Net Income	-$166.3M-106.6%	-$80.5M-16.1%	-$69.3M
EPS (Diluted)	$-4.32-68.8%	$-2.56	$-32.38

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$32.2M+16.0%	$27.7M-54.8%	$61.3M	N/A	$20.1M-7.8%	$21.8M+28.3%	$17.0M
SG&A Expenses	N/A	$6.1M+4.2%	$5.9M+7.7%	$5.5M	N/A	$4.1M+5.7%	$3.9M+5.9%	$3.7M
Operating Income	N/A	-$38.3M-14.0%	-$33.6M+49.6%	-$66.8M	N/A	-$24.2M+5.7%	-$25.7M-24.3%	-$20.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$35.0M-11.4%	-$31.4M+51.2%	-$64.4M	N/A	-$20.6M+6.0%	-$21.9M-25.6%	-$17.4M
EPS (Diluted)	N/A	$-0.83+7.8%	$-0.90+52.6%	$-1.90	N/A	$-0.61+6.2%	$-0.65+7.1%	$-0.70

AVBP Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$333.2M+21.2%	$274.9M+68.6%	$163.1M
Current Assets	$332.9M+46.7%	$227.0M+41.9%	$160.0M
Cash & Equivalents	$45.5M-38.7%	$74.3M-50.6%	$150.4M
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$25.9M+50.1%	$17.3M-94.5%	$316.3M
Current Liabilities	$25.9M+50.2%	$17.3M+48.6%	$11.6M
Long-Term Debt	N/A	N/A	N/A
Total Equity	$307.2M+19.2%	$257.7M+268.2%	-$153.2M
Retained Earnings	-$404.6M-69.8%	-$238.3M-51.0%	-$157.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$333.2M+2.0%	$326.6M+21.2%	$269.5M+25.1%	$215.5M-21.6%	$274.9M-6.1%	$292.7M-5.2%	$308.9M-5.8%	$327.8M
Current Assets	$332.9M+3.6%	$321.2M+28.4%	$250.1M+34.6%	$185.8M-18.1%	$227.0M-22.4%	$292.4M-5.2%	$308.5M-5.8%	$327.5M
Cash & Equivalents	$45.5M-59.6%	$112.7M-0.1%	$112.8M+126.1%	$49.9M-32.9%	$74.3M-73.7%	$282.9M-5.3%	$298.7M-5.9%	$317.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$25.9M+20.3%	$21.6M+9.8%	$19.6M+51.6%	$13.0M-25.1%	$17.3M+13.6%	$15.2M+24.8%	$12.2M+20.6%	$10.1M
Current Liabilities	$25.9M+20.3%	$21.6M+9.8%	$19.6M+51.6%	$13.0M-25.0%	$17.3M+13.9%	$15.2M+25.3%	$12.1M+21.3%	$10.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$307.2M+0.7%	$305.0M+22.1%	$249.9M+23.4%	$202.5M-21.4%	$257.7M-7.1%	$277.5M-6.5%	$296.7M-6.6%	$317.7M
Retained Earnings	-$404.6M-9.6%	-$369.1M-10.5%	-$334.1M-10.4%	-$302.7M-27.0%	-$238.3M-9.5%	-$217.7M-10.4%	-$197.1M-12.5%	-$175.3M

AVBP Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$160.6M-128.7%	-$70.2M-25.7%	-$55.8M
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	-$71.2M+63.0%	-$192.5M	N/A
Financing Cash Flow	$203.1M+8.8%	$186.6M+335.3%	$42.9M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$30.7M+14.4%	-$35.8M-37.0%	-$26.1M+61.6%	-$68.0M-321.1%	-$16.2M+1.2%	-$16.3M+14.4%	-$19.1M-2.5%	-$18.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$71.2M-40.3%	-$50.8M-464.9%	$13.9M-62.2%	$36.8M	N/A	N/A	N/A	N/A
Financing Cash Flow	$34.7M-59.8%	$86.5M+15.1%	$75.1M+1011.3%	$6.8M+12189.1%	$55K-89.6%	$531K+46.3%	$363K-99.8%	$185.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AVBP Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A
Return on Equity	-54.1%-22.9pp	-31.2%	N/A
Return on Assets	-49.9%-20.6pp	-29.3%+13.2pp	-42.5%
Current Ratio	12.83-0.3	13.14-0.6	13.76
Debt-to-Equity	0.08+0.0	0.07+2.1	-2.06
FCF Margin	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-11.5%+1.1pp	-12.6%+19.2pp	-31.8%	N/A	-7.4%-0.0pp	-7.4%-1.9pp	-5.5%
Return on Assets	N/A	-10.7%+0.9pp	-11.7%+18.2pp	-29.9%	N/A	-7.0%+0.1pp	-7.1%-1.8pp	-5.3%
Current Ratio	12.83-2.1	14.90+2.2	12.74-1.6	14.34+1.2	13.14-6.1	19.28-6.2	25.50-7.3	32.82
Debt-to-Equity	0.08+0.0	0.070.0	0.08+0.0	0.060.0	0.07+0.0	0.05+0.0	0.040.0	0.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Day One Biopharmaceuticals, Inc. DAWN

$2.2B

Kura Oncology Inc KURA

$760.5M

Tango Therapeutics Inc TNGX

$3.1B

Immunome Inc IMNM

$2.5B

Praxis Precision Medicines, Inc. PRAX

$8.6B

Frequently Asked Questions

Is Arrivent Biopharma Inc profitable?

No, Arrivent Biopharma Inc (AVBP) reported a net income of -$166.3M in fiscal year 2025.

What is Arrivent Biopharma Inc's EBITDA?

Arrivent Biopharma Inc (AVBP) had EBITDA of -$180.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Arrivent Biopharma Inc's return on equity (ROE)?

Arrivent Biopharma Inc (AVBP) has a return on equity of -54.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Arrivent Biopharma Inc's operating cash flow?

Arrivent Biopharma Inc (AVBP) generated -$160.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Arrivent Biopharma Inc's total assets?

Arrivent Biopharma Inc (AVBP) had $333.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Arrivent Biopharma Inc spend on research and development?

Arrivent Biopharma Inc (AVBP) invested $153.4M in research and development during fiscal year 2025.

How many shares does Arrivent Biopharma Inc have outstanding?

Arrivent Biopharma Inc (AVBP) had 42M shares outstanding as of fiscal year 2025.

What is Arrivent Biopharma Inc's current ratio?

Arrivent Biopharma Inc (AVBP) had a current ratio of 12.83 as of fiscal year 2025, which is generally considered healthy.

What is Arrivent Biopharma Inc's debt-to-equity ratio?

Arrivent Biopharma Inc (AVBP) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Arrivent Biopharma Inc's return on assets (ROA)?

Arrivent Biopharma Inc (AVBP) had a return on assets of -49.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Arrivent Biopharma Inc's cash runway?

Based on fiscal year 2025 data, Arrivent Biopharma Inc (AVBP) had $45.5M in cash against an annual operating cash burn of $160.6M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Arrivent Biopharma Inc's Piotroski F-Score?

Arrivent Biopharma Inc (AVBP) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Arrivent Biopharma Inc's earnings high quality?

Arrivent Biopharma Inc (AVBP) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.